CinnaGen Co., established in 1994, has built a reputation as the leading Biopharma manufacturer and biotech exporter in its region. With its origins grounded in biotechnology, the company's commitment to R&D is evident in its allocation of over 20% of its turnover to this area. This investment underpins CinnaGen’s capacity to develop cutting-edge biotechnological products, particularly in the fields of immunological diseases and oncology.
The company's evolution from producing enzymes and PCR kits to entering the therapeutic recombinant protein market underscores its strategic growth. CinnaGen also focuses on leveraging its expertise through strategic partnerships and contract research services. Such efforts align with its slogan, "Our Ambition is Beyond Imagination", positioning it to sustainably advance human health.
For investors, CinnaGen represents a dynamic player with substantial potential, given its established market presence and strategic focus on biogenerics and innovation.